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Immune pressureCytotoxic T-lymphocyte (CTL) epitopes within the HIV genome are subject to negative and positive selective
pressures, the balance of which inﬂuences CTL escape at a given epitope. We investigated whether viral
ﬁtness requirements dictate conservation of the HLA-A2 restricted immunodominant epitope SLYNTVATL
(SL9). Viral clones incorporating changes throughout the SL9 epitope region were compared to consensus
SL9 virus in terms of replication kinetics and relative viral ﬁtness. Constructs recapitulating in vivo SL9-CTL
escape variants showed markedly little effect on replication and ﬁtness, as did non-natural conservative
mutations targeting immunologically relevant positions of the epitope. Although certain residues of the
epitope were constrained by viral requirements, our research reveals that there are multiple SL9 variants that
are well tolerated virologically but fail to arise in vivo. In light of this data, assumptions regarding the balance
of immune and viral selective pressures on this immunodominant epitope sequence need to be reassessed.
© 2009 Elsevier Inc. All rights reserved.IntroductionNearly a quarter century since the discovery of the Human
Immunodeﬁciency Virus (HIV), we are faced with worldwide disease
of unprecedented proportions (Barre-Sinoussi et al., 1983; Broder and
Gallo, 1984; UNAIDS and WHO, 2006). Yet, despite intensive research
efforts, an effective HIV vaccine has not been introduced. Daunted by
the incredible diversity of the envelope protein among viral clades
and the failure of initial recombinant gp120 based vaccines (Moore
et al., 1994; Pantophlet and Burton, 2006), many investigators have
focused on CD8+ T-cell responses, citing the evidence from acute
HIV infection (Koup et al., 1994; Ogg et al., 1998), association of HLA
class I alleles with disease progression (Altfeld et al., 2003;
Carrington and O'Brien, 2003; MacDonald et al., 1998, 2000), exposed
uninfected individuals (Fowke et al., 2000; Kaul et al., 2001a) and
CD8 depletion studies in macaques (Jin et al., 1999; Schmitz et al.,
1999) as support for a strong role of CD8+ T-cell mediated immunity
in control of HIV progression. Therefore, most recently, vaccine
design has focused on eliciting potent CD8+ T-cell responses, as they
target viral gene products which are well conserved across viral
clades and could be more thoroughly cross-protective (Letvin, 2006;y, Mount Sinai Hospital, 600
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ll rights reserved.McMicheal and Rowland-Jones, 2001). As such, HIV vaccine research
has moved towards developing strategies that maximally stimulate
responses to CTL epitopes in the hopes of achieving immune
protection either on their own or in combination with antibody-
based strategies.
The rapid evolution of mutations in a CD8 epitope can be seen as a
measure of the strength of CD8+ effectors. Many CD8 epitopes in HIV
acquire these changes which lead to the subsequent loss of
recognition by the original T-cell responses (Borrow et al., 1997; Cao
et al., 2003; Draenert et al., 2004), otherwise known as CTL escape.
The selection of these mutations supports the idea that in vivo these
responses are placing pressure on the infection by restricting
replication of virus containing recognized epitope sequences (Borrow
et al., 1997; Moore et al., 2002; Overbaugh and Bangham, 2001) while
also indicating that strong CD8+ T-cell responses to HIV epitopes may
not be long lasting in vivo. What remains unclear is whether individual
CD8+ T-cell responses are contributing equally to the control of viral
replication and selection of escape variants. Recent studies have
illustrated that CD8+ T-cell responses targeting Gag are more
commonly associated with low HIV viral loads than those directed
at Env or regulatory proteins (Jiao et al., 2006a, 2006b; Kiepiela et al.,
2007). Other studies have highlighted CD8+ T-cell responses that are
successful in restricting viral replication and reﬁned the effector
function attributed to particular T-cell clones (Varela-Rohena et al.,
2008). The results of these, and numerous other studies, underline a
Table 2
Panel of engineered HIV infectious clones with congenic changes to the SL9 epitope
region.
All mutations were incorporated into the pLAI.2 background. Constructs were named
based on the consensus amino acid, the epitope position, and the post-mutation
amino acid. Eight constructs (⁎) were designed to represent natural variants of SL9
documented in HLA-A2+ HIV+ individuals (Iversen et al., 2006). A further 10
constructs (§) were engineered to investigate the effect of amino acid alterations not
previously documented in vivo (artiﬁcial variants). Two constructs were engineered
incorporating synonymous mutations to investigate the signiﬁcance of the region in
RNA processing and trafﬁcking. Eight constructs incorporated artiﬁcial non-
synonymous changes to immunologically important positions of the epitope to
determine if the narrow range of SL9 CTL variants in vivo is due to negative effects of
mutation on viral growth or ﬁtness. Nucleotide changes from consensus pLAI.2 are
underlined. Putative TCR contacts (positions 5 and 6) and HLA anchor (position 9) are
highlighted in shaded boxes. A secondary HLA anchor has been described at position 2.
138 N.M. Christie et al. / Virology 388 (2009) 137–146dual requirement for a vaccine that induces CTL responses: namely,
responses must be fully functional and place effective pressure on
replicating virus in addition to targeting epitopes that would be
unlikely to change in the face of immune pressures (Goulder and
Watkins, 2004). Epitope sequences that are essential to viral function
would therefore be the best vaccine targets (Altfeld and Allen, 2006),
as mutations that did emerge in response to CTL immune pressures
would likely be quickly removed from the viral quasispecies due to
resultant impairment of viral replication and the target sequence
would be retained.
One of the regions of the HIV genome that is both conserved and
highly immunogenic is the Gag open-reading frame (Korber et al.,
2005; Leitner et al., 2005). The structural nature of the proteins
encoded in this region, suggest that amino acid mutations at key
residues could destabilize protein interactions and impact viral
assembly. Of the numerous CD8+ T-cell epitopes encoded in Gag,
the SLYNTVATL (SL9) epitope has been extensively studied. Although
this epitope is located in p17 subunit of Gag, rather than the more
conserved p24, the importance of p17 during viral entry, nuclear
import of HIV DNA and late infection has been clearly demonstrated
(Cannon et al., 1997; Freed et al., 1994; Ono et al., 2000). Furthermore,
this epitope is particularly interesting because it is restricted by the
most common HLA determinant worldwide, the HLA-A2 supertype
(Brander et al., 1998; Goulder et al., 1997) and numerous studies have
noted that between 50–70% of A2+ individuals target this epitope in
an immunodominant manner during chronic infection (Brander et al.,
1998; Goulder et al., 2001a; Ogg et al., 1998; Scott-Algara et al., 2001).
Investigations by ourselves and others regarding SL9 epitope escape
have shown that the sequence shows considerable conservation over
time as a very narrow range of epitope variants develop slowly, if at all,
and that immunologic reactivity to autologous variants is often
preserved (Brander et al., 1998; Iversen et al., 2006; Lopez et al., 2006).
The delayed emergence and limited breadth of variants has been
suggested to be due to perturbations during viral assembly (Iversen et
al., 2006). However, other observations suggest that the SL9-speciﬁc
response may not be placing efﬁcient pressure on the epitope
sequence. Studies point to the rarity of this response during the
acute stage of HIV infection (Goulder et al., 2001a) the maintenance of
SL9 as an immunodominant response throughout chronic infection
(Buseyne et al., 2002; Goulder et al., 2001a; Schmitt-Haendle et al.,
2005), and differential HLA-A2-restricted epitope targets observed in
the CTL responses of HIV-resistant individuals (Fowke et al., 2000;
Kaul et al., 2001a). In fact, in the case of highly exposed persistently
seronegative (HEPS) individuals, the SL9 response is only rarely
detected during seronegative status but becomes dominant after rare
cases of HIV seroconversion (Kaul et al., 2001b), adding to the
evidence suggesting that this response is not associated with effective
immune responses to HIV.
Given the predominance of immune rather than virological
investigation of the balance of pressures on the SL9 epitope, we
investigated the impact of mutations within the SL9 epitope on HIV
replication. We created congenic variants over the epitope region and
tested the ability of these viruses to expand in vitro and compete with
SL9 consensus encoding virus. In order to determinewhether the slowTable 1
Synonymous Vif cassettes in pLAI.2.
HIV infectious
plasmid
Vif sequence (4879 bp–4919 bp)
pNL4-3 (vifA) 5′ - TAG AAT GGA GGA AAA AGA GAT ATA CCA CAC AAC TAG ACC C - 3′
pLAI.2 (vifA)† 5′ - TAG AAT GGA GGA AAA AGA GAT ATA GCA CAC AAG TAG ACC C - 3′
pLAI.2 (vifB)† 5′ - TAG AAT GGAGGA AGA AAA GGT ATA CCA CGC AGG TGG ACC C - 3′
Sequence of the 40 bp vifA cassette in the original context of pNL4-3; the sequence of
vifA in pLAI.2 with differences from pNL4-3vifA (in bold); the sequence of vifB in pLAI.2
with differences from pLAI.2vifA (underlined). The plasmids marked with † were
constructed for our studies.emergence of SL9 mutations in HLA-A2+ individuals is due to
compromised viral ﬁtness, we recapitulated variant SL9 epitope
sequences that have been observed in vivo (Goulder et al., 2001b;
Iversen et al., 2006; Leitner et al., 2005). We were also interested in
SL9 epitope sequences that, to date, have not been observed in vivo,
but would have the potential to disrupt immune recognition. There-
fore, we constructed mutations of MHC anchor and T-cell receptor
(TCR) contact residues (Rammensee et al., 1999) within the epitope in
order to investigate the possibility that these mutations are excluded
from the viral quasispecies during natural infection due to prohibitive
viral ﬁtness consequences.
Here we report that multiple amino acid substitutions are in fact
tolerated throughout the SL9 epitope without signiﬁcant impact on
viral production or infectivity in vitro. Viral constructs encoding
previously reported putative in vivo CTL escape variants of the
epitope showed equivalent growth and ﬁtness to consensus SL9
encoding virus. This evidence suggests that the slow emergence of
epitope variants in vivo may not be linked to effects on viral ﬁtness.
Furthermore, we demonstrate that conservative non-natural (never
observed in vivo) amino acid changes to residues affecting immune
recognition of this epitope have no effect on viral growth. This
ﬁnding indicates that, based on viral replication requirements, a
wider repertoire of SL9 epitope variants encoding changes at
immunologically important residues should evolve in vivo than has
been reported thus far. Taken collectively, these observations indicate
that the limited range of variation seen in the SL9 epitope sequence
may not be solely due to the negative viral impact of mutations in
this region. Ultimately, this suggests that the understanding of the
balance between CTL mediated pressures on the SL9 epitope and
the viral replication requirements of this region of Gag need to be
reassessed.
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Incorporation of synonymous vif cassettes into pLAI.2
Detection of viral variants in dual-infection competition culture
relies on signiﬁcant sequence variation between the two viruses in
question. The SL9 variations incorporated into pLAI.2 did not differ
sufﬁciently from consensus SL9 sequence to be reliably detected in a
heteroduplex tracking assay (HTA). Therefore, we adapted a synon-
ymous mutation strategy extensively used within the context of the
pNL4-3 infectious viral construct (Liu et al., 2007; Lobritz et al., 2007).
This approach used synonymous variation throughout a 40 bp region
of the HIV vif gene as a surrogate marker for certain viral variants. The
natural sequence of pLAI.2 throughout this region was termed vifA
and varied from that of pNL4-3 at two residues (Table 1). The SL9
epitope variants were subsequently constructed on this background
and therefore encoded the vifA sequence. A second pLAI.2 background
was engineered to contain the vifB sequence analogous to that
implemented in the pNL4-3 system (Table 1). This provided sevenFig. 1. Expansion of infectious SL9 mutated HIV-1 clones in U87.CD4.CXCR4 cells. Supernatant
viral constructs was monitored by p24 production in the culture supernatant. Supernatant w
shown is from representative experiments. (A) Growth of natural SL9 variants. (B) p24 pr
variants (T5S, V6L, L9I and L9L) expanded well and were subsequently termed “viable artiﬁc
expansion on the U87.CD4.CXCR4 cells and were thus termed “non-viable artiﬁcial variantsnucleotide differences throughout this vif cassette, which has been
shown to be sufﬁcient for resolution in HTA analysis (Arts, E.J.,
personal communication). In mono-infections assays, the LAIvifA and
LAIvifB viruses grew equivalently with respect to both kinetics and
magnitude, and analysis of dual-infection assays by HTA conﬁrmed
that the two viruses were equally ﬁt (Fig. 5, Supplementary Fig. 1).
Production and puriﬁcation of SL9 congenic viruses
We produced a panel of nineteen SL9 mutations and assessed their
ability to grow in vitro (Table 2). This panel included eight SL9
sequences previously identiﬁed in HIV infected individuals (Iversen
et al., 2006; Lopez et al., 2006) (termed “natural variants”) in addition
to eight sequences that have not been observed in vivo (termed
“artiﬁcial variants”). The natural variants represent a narrow range of
sequence variation concerning the third, sixth and eighth residues of
the epitope. These variants can exist in various combinations with SL9
consensus and each other in vivo (Iversen et al., 2006) and these
combinations make up 76.6% of the variants of the epitopefrom 293T cell cultures was used to infect U87.CD4.CXCR4 cells. Expansion of infectious
as collected and used as viral stocks at peak p24 values, as indicated by arrows— . Data
oduction following U87.CD4.CXCR4 infection with artiﬁcial SL9 variants. Four of these
ial variants”. The remaining six viruses (SYN, T5A, T5D, V6A, V6K and L9A) did not show
”.
Fig. 2. Growth of HIV-1 clones encoding natural variations of the SL9 epitope in CEM-T4 cells. Viral stocks resulting from the passage of viral particles over U87.CD4.CXCR4 cells were
titrated and subsequently used to infect CEM-T4 cells at anMOI of 0.01. All infections were done in triplicate and resultant error bars are plotted. Samples were subsequently removed
from the culture supernatant every 3 days to assess p24 concentration as a measure of viral growth. At 9 dpi, the constructs V6I/T8V, Y3F/V6I/T8V and Y3F/T5A/T8V showed
signiﬁcantly higher p24 production than the remainder of the constructs (⁎pb0.05). However, samples taken at 12 dpi reveal no signiﬁcant differences in peak levels of expansion
between the viruses. All infections were run in triplicate.
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2006/2007). The artiﬁcial variants speciﬁcally target immunologically
relevant residues within the epitope with changes that have never
been observed in nature. We targeted our changes to positions 5 and 6
(TCR contacts) and position 9 (MHC anchor) (Falk et al., 1991;
Rammensee et al., 1999; Yang et al., 1996) as changes at these residuesFig. 3. Growth of HIV-1 clones containing targeted artiﬁcial mutations in the SL9 epitope afte
CD4.CXCR4 cells were titrated and subsequently used to infect CEM-T4 cells at an MOI o
concentration as a measure of viral growth. All viruses expanded to comparable levels, with
whereas other viral cultures began showing p24 production above input values at the ﬁrst s
and 14 dpi (⁎⁎pb0.01). However, by 16 dpi p24 production from the L9I infected cells hadin vivo would be the most likely to affect the epitope binding to HLA
molecules and the subsequent T-cell recognition of this complex.
Although the second position of the epitope has also been reported to
function as a weak secondary MHC anchor (Rammensee et al., 1999),
variation at this residue is seen to be tolerated in vivo (Leitner et al.,
2005). During the selection of amino acid changes, we consideredr infection of CEM-T4 cells. Viral stocks resulting from passage of viral particles over U87.
f 0.01. Samples were taken from the culture supernatant every 3 days to assess p24
the exception of L9I. No p24 production was detected from this viral culture until 9 dpi,
ample time point of 4 dpi. L9I produced signiﬁcantly less p24 compared to LAI at 12 dpi
reached similar levels as the other viral cultures. All infections were run in triplicate.
Fig. 4. Localization of p24 following exposure of U87.CD4.CXCR4 cells to congenic SL9
viral particles. Artiﬁcial viral variants were comparatively assessed for cellular vs.
released p24. Cells and supernatant were collected 6 days post-infection of U87.CD4.
CXCR4 cells. Supernatants were puriﬁed and cells were lysed in order to determine the
relative amounts of p24 released from or retained in the cells. Non-viable constructs are
denoted by † and the majority of these constructs, which showed little to no ability to
expand in U87.CD4.CXCR4 culture, also showed very minimal p24 production both
extracellularly and intracellularly. Among the non-viable artiﬁcial constructs, intracel-
lular p24 was detected only in cells infected with the L9A virus. Experiments were run
in triplicate wells to derive average p24 concentrations and standard deviations.
141N.M. Christie et al. / Virology 388 (2009) 137–146both the disruption to matrix protein structure and the potential
immune evasion beneﬁts in order to determine a panel of variants that
ranged from conservative to non-conservative substitutions (Table 2),
In addition, we created two synonymously mutated constructs (SYN
and L9L). The SYN variant assessed the affect of multiple RNA changes
over the SL9 epitope region. Our previous studies of SL9 epitope
sequences in vivo (data not shown, Iversen et al., 2006), had indicated
that the terminal codon was very highly conserved, even at the DNA
level. Therefore, the L9L variant examined the speciﬁc effects of single
nucleotide changes at this codon.
Following transfection of plasmids into 293T cells and a single
round of puriﬁcation through U87.CD4.CXCR4 cells, thirteen of the
nineteen viral constructs exhibited substantial expansion (Figs.1A and
B) and produced high titer viral stocks (1×105 IU/mL; range 103.5 IU/
mL–106 IU/mL) andwe termed these “viable” SL9 variants. Notably, all
of the natural variants expanded well during this passage (Fig. 1A).
Four of the artiﬁcial variants were seen to expand and were thus
termed “viable artiﬁcial” SL9 variant viruses.Wewere unable to detect
expansion of six viral variants (Fig. 1B) and refer to these as “non-
viable artiﬁcial” SL9 variants. These non-viable artiﬁcial variants were
comprised of: non-conservative amino acid changes to the TCR
contact region of the epitope (T5D, V6K), alanine substitutions at
these TCR residues (T5A, V6A), alanine substitution at the terminal
leucine residue (L9A) and synonymous mutations throughout the SL9
epitope and ﬂanking region (SYN). Sequencing data of the 570 bp
region surrounding the SL9 epitope at regular time points during the
process of preparing viral stocks revealed no reversion or compensa-
tory mutations in any of the resultant viruses (data not shown).
Growth of SL9 variant viruses in CEM-T4 cells
Growth of each viable SL9 variant virus was monitored in equal
MOI cultures of CEM-T4 cells. The growth kinetics of SL9 mutations
that mimic natural variants (Table 2) were seen to closely align with
that of the consensus SL9 LAI (Fig. 2). There was no evidence of
negative effects of these natural SL9 mutations on viral assembly or
production relative to consensus LAI. Interestingly, three of the natural
variants showed signiﬁcantly faster replication kinetics than LAI (V6I/
T8V, Y3F/V6I/T8V, and Y3F/T5A/T8V; pb0.05) as indicated by higher
levels of p24 release at day 9 post-infection when compared to the
respective p24 measurement for the LAI control at this time point
(Fig. 2). Furthermore, all of the viable artiﬁcial SL9 variants grew with
similar kinetics andmagnitudes as the SL9 consensus LAI control virus
with the exception of L9I. The L9I variant exhibited signiﬁcantly
delayed growth kinetics (pb0.01), with detectable p24 appearing
after 9 days in culture (Fig. 3). We conﬁrmed that the virus present in
cultures retained the desired mutations, including L9I at day 9 and
later (data not shown).
Localization of p24 in viable vs. non-viable artiﬁcial SL9 variants
The six constructs that failed to expand upon passage through U87.
CD4.CXCR4 cells were termed “non-viable artiﬁcial” SL9 variants
(Fig. 1B). To further investigate this lack of viral production, the levels
of released and intracellular p24 were assessed six days after
application of transfection supernatants to U87.CD4.CXCR4 cells.
Because virus did not expand efﬁciently from these constructs, the
inoculum could not be equalized based on infectious titer. Therefore,
in order to ensure that levels of p24 recovered from U87.CD4.CXCR4
cell cultures were comparable for all viral constructs, the inoculum
was equalized based on p24 content of the transfection supernatants.
Cultures inoculated with viable artiﬁcial SL9 variants (LAI, T5S, V6L,
L9I and L9L) showed robust levels of p24 in both the cellular and
released compartments (Fig. 4) and deﬁnitemorphological changes in
the cultures characteristic of infection (data not shown). However,
cultures exposed to non-viable viral particles encoding SYN, V6A andV6K exhibited no signs of cytopathic effects (CPE) and no p24 was
detected in either the supernatant or the intracellular compartment
(Fig. 4). Notably, all position nine variants seemed to allow for
infection of cells (visual observation based on morphology; data not
shown due to lack of photography capability in containment facility)
but there appeared to be a disruption in the release of virions from the
infected cells: L9A demonstrated p24 production only in the cellular
fraction (Fig. 4), whereas L9I resulted in both cellular and delayed
released p24 (Fig. 3), and L9L showed cellular and released p24 at a
comparable ratio to LAI consensus SL9 sequence (Fig. 4). Interestingly,
residues directly downstream of the SL9 epitope have been implicated
in virion assembly and release of infectious virions (Bukrinskaya,
2007; Freed et al., 1994; Saad et al., 2006). Although our data highlight
a potential defect in cellular localization of the matrix protein (p17) of
HIV, these results are highly preliminary and need to be repeated and
expanded upon for any signiﬁcant conclusions to be made.
Replicative ﬁtness of natural SL9 variants
Following dual-infection PBMC competition culture against con-
sensus SL9 virus (LAIvifB), relative ﬁtness values (w) were calculated
for the eight natural SL9 variant viruses. Equivalent relative ﬁtness of
consensus SL9 viruses was conﬁrmed by HTA densitometry measure-
ments determining that the relative ﬁtness value for LAIvifB with
respect to LAIvifA was 1.0 (Fig. 5). This indicated that after 7 days in
competition culture, each virus comprised 50% of the total virus
population. As such, alterations made to generate LAIvifB appeared to
have no effect on replicative ﬁtness when compared to LAIvifA. The
natural SL9 variants under investigation are hypothesized to con-
stitute partial CTL escape variants in vivo and are speculated to have
compromised viral ﬁtness to evade immune responses (Iversen et al.,
2006). Interestingly, of the panel of nine natural SL9 variant viruses
we constructed, none showed any signiﬁcant decreases in ﬁtness
compared to consensus SL9 virus (Fig. 5A). Four viruses were seen to
compete equally with consensus virus (T8V, Y3F/V6I, V6I/T8V, and
Y3F/T5A/T8V) whereas four variants demonstrated signiﬁcantly
Fig. 5. Relative ﬁtness values derived from competition assay growth of SL9 mutated viruses in the presence of SL9 consensus virus. Growth of viral variants was assessed relative to
consensus virus using a dual-infection assay. SL9 congenic viruses (LAIvifA background) were placed in direct competitionwith SL9 consensus virus (LAIvifB). Relative amounts of variant
and consensus proviral DNAwere measured 7 dpi using a heteroduplex tracking assay (HTA). Black columns represent the relative ﬁtness values derived from competition between SL9-
consensus containing LAIvifA and LAIvifB. A relativeﬁtness value of 1.0 represents equal amounts of LAIvifB andvariant virus in the culture and is therefore indicative of equalﬁtness (dotted
line). (⁎pb0.05, ⁎⁎pb0.01, ⁎⁎⁎pb0.001). All assays were run in triplicate. (A) Relative ﬁtness values for natural SL9 variants. Grey columns are single variants. Angled striped columns are
double variants. Checkered columns are triple variants. (B) Relative ﬁtness values for SL9 viable artiﬁcial variants. Non-synonymous variants are white columns. Striped columns are
synonymous variants.
142 N.M. Christie et al. / Virology 388 (2009) 137–146increased ﬁtness (V6I — pb0.001, Y3F and Y3F/T8V — pb0.01, Y3F/
V6I/T8V — pb0.05) (Fig. 5A).
Replicative ﬁtness of artiﬁcial SL9 variants
Competition cultures against consensus SL9 virus, LAIvifB, were
also used to determine relative ﬁtness values (w) for the four viable
artiﬁcial SL9 variants. These values indicated that three of the four
artiﬁcial variants were equal to or exceeded the ﬁtness of the
consensus SL9 virus (Fig. 5B). Interestingly, the L9L (pb0.001) and
L9I (pb0.01) viruses showed signiﬁcantly increased ﬁtness, out-
growing the consensus virus (Fig. 5B). V6L was the only virus with a
relative ﬁtness value signiﬁcantly lower than consensus (w=0.829;
pb0.05). This equates to a situation where V6L would comprise
41.5% of the culture swarm of viruses at 7 dpi (Fig. 5B).Discussion
In this study, we have investigated virologic pressures that may
impede the development of CTL escape mutations of the immunodomi-
nant epitope SLYNTVATLduringHIV infection.Using congenic variants of
the SL9 epitope, our observations suggest that conservativemutations at
immunologically important residues within the SL9 epitope are well
tolerated by the virus (Fig. 3). Although previous investigations had
assumed that in vivo variants of SL9 were slow to develop due to
replicative barriers imposed by the immune evasion mutations (Iversen
et al., 2006), we have demonstrated that these natural SL9mutations are
not limited in their ability to grow efﬁciently in culture (Fig. 2) or to
compete with consensus SL9 virus in dual-infection assays (Fig. 5A).
Interestingly, our investigation indicates that more variation could
be tolerated at amino acid residues crucial to the recognition of the
143N.M. Christie et al. / Virology 388 (2009) 137–146SL9 peptide without compromising the ability of these HIV variants to
replicate. Conservative mutations at immunologically important
residues within the SL9 epitope, that are never seen in the natural
quasispecies of HIV, do not impair replication (Fig. 3) and these
artiﬁcial SL9 variants, with the exception of V6L, show viral ﬁtness
equivalent to or superceding that of consensus SL9 virus (Fig. 5B). This
suggests that were these mutations to evolve in vivo they would at
least be capable of sustaining themselves within the viral quasispe-
cies. It should be noted that we designed our study to focus on the
affects of amino acid mutations within the SL9 epitope. Selective
pressures may also limit evolution of SL9 escape variants through
conservation of RNA structures (Kijak et al., 2004). In our limited
study of synonymous mutations we observed that the SYN variant
encoding 8 synonymous changes throughout the epitope was not
viable (Fig. 1B). However, a construct encoding a single synonymous
change, L9L, was unaffected in viral growth or ﬁtness (Figs. 1B, 3 and
5). This incorporation of a single synonymous change would most
likely bemore representative of the steps towards the accumulation of
immune escape mutations. Further study would be required to
determine whether RNA structure at key epitope residues plays a
role in SL9 conservation, however our observations have underscored
previous evidence that the RNA sequence throughout this region of
Gag may be involved with HIV genome packaging and the production
of fully functional viruses (Fiorentini et al., 2006; Freed et al., 1994).
The utility of competitive infection assays in determining relative
viral ﬁtness has been clearly shown in the literature (Liu et al., 2007;
Lobritz et al., 2007) and they have been seen to accurately represent
ex vivo ﬁtness measurements (Ball et al., 2003; Quinones-Mateu
et al., 2000). Despite these precedents, one of the main shortcomings
in our investigation of viral ﬁtness of SL9 mutations is the use of LAI as
the background for our mutations. This viral strain is X4-tropic and is
therefore expected to show accelerated kinetics of viral infection and
cell death in PBMC culture when compared to ex vivo strains of HIV.
However, we felt it was very important to use a well-characterized
laboratory strain of HIV so that we could be conﬁdent regarding our
observations of growth kinetics and any changes that might result
after SL9 mutations were introduced. Furthermore, the fast expansion
of this viral strain in vitro allows for a dual-infection ﬁtness assay that
is relatively short at 7 days, decreasing the need for continual feeding
of PBMCs into the culture, which can in turn introduce contaminants.
Although many of the complexities of natural HIV infection are not
recapitulated in our in vitro assays of viral ﬁtness, it is important to
note that in our competitive assays there is no substitute for
immunological pressures that are present in the natural setting. If
one assumes that such pressures would be anticipated to impart a
ﬁtness advantage to non-consensus SL9 viruses through increased
survival due to immune evasion, any ﬁtness equality or advantage that
these variants demonstrated in our in vitro assays might actually be
exaggerated in vivo. The observations presented in this report suggest
that we must revisit assumptions that regard ﬁtness as the primary
cause of conservation of the SL9 sequence and challenge us to
question why the evolution of SL9 variants viruses in vivo is restricted
to a narrow range of variants in this immunodominant HIV epitope.
Ultimately the balance between host immune pressure, favouring
sequence diversiﬁcation away from recognized epitopes, and viral
pressure aimed at conserving sequences that provide optimal growth
characteristics, determines whether CTL escape is possible at a given
epitope (Ganusov and De Boer, 2006). Indeed, there are examples of
mutations within CTL epitopes where viral ﬁtness is drastically
impaired for the sake of immune evasion (Fernandez et al., 2005; Liu
et al., 2007; Loh et al., 2007; Martinez-Picado et al., 2006). Because of
this evidence, it has been widely believed that conservation of
immunodominant epitope sequences in HIV, such as SL9, indicates an
insurmountable viral ﬁtness pressure counteracting the immune
pressure. However, in this study we have demonstrated that this is
not the case in the context of the high degree of conservationobserved in ex vivo studies of viral SL9 quasispecies (Brander et al.,
1998; Iversen et al., 2006; Lopez et al., 2006). By illustrating that
these natural SL9 variants are no less ﬁt than consensus SL9
containing virus, our study suggests that the understanding of
selective pressures in the setting of this immunodominant epitope in
vivo has been over-simpliﬁed and confronts us with questions
regarding the efﬁcacy of the immune pressure levied against this
epitope. If the viral pressures that were thought to be maintaining
this epitope sequence are less than previously thought, it is hard to
imagine that the opposing immunological pressures are as strong as
previously assumed.
There is now considerable effort focused on understanding the
diversity of effector functions within the larger CD8+ T-cell popula-
tion with emphasis on the cytokine quality and phenotype of effector
responses versus the magnitude of responses as deﬁned by secretion
of a single cytokine or the presence of cytolysis (Betts et al., 2004; Fu
et al., 2007; Leslie et al., 2006). Indeed the ﬁeld of CTL vaccinology as a
whole has been forced to reconsider a number of assumptions with
the premature termination of the Merck STEP Trial (HVTN 502)
(Hanke, 2008; Moore et al., 2008; Sekaly, 2008). Alongside detailed
analysis of the mechanisms involved in the failure of this speciﬁc trial,
the ﬁeld of HIV immunology also needs to recognize that there is a
fundamental gap in our understanding of the full spectrum of
functionality, speciﬁcity and magnitude of anti-HIV cellular immune
responses. Indeed, just as non-neutralizing antibodies or even
enhancing antibodies have been seen in many natural infections,
CD8+ T-cell responses may well have a spectrum of actions and
effector states that deﬁne their ability to offer a protective effect or
lack thereof.
However, to date a complete knowledge of the breath and nature of
CTL antiviral functionality has yet to be determined, so we have taken
a reductionist approach and applied the concept of evolutionary
equilibrium in our studies. We examined a surrogate for the
cumulative immune pressure on the SL9 epitope by measuring the
cumulative virological ﬁtness pressure that balances it. This has the
beneﬁt of allowing us to make observations about the cumulative
effect of this particular CTL responsewithout a complete knowledge of
the peculiarities of its functional nature. Observations regarding
differential rates of CTL escapemutation in HIV epitopes are starting to
drive the development of new methods to more accurately measure
the extent of pressure on CD8+ T-cell epitopes (Mandl et al., 2007).
We have illustrated a situation in which the lack of mutations within
an immunodominant epitope during the course of HIV infection does
not indicate sequence conservation driven by viral pressures. Indeed,
further immunologic study of the SL9 epitope targeted response may
well indicate that a qualitatively less effective although robust
immune response is directed towards this immunodominant epitope.
As such, vaccines that elicit SL9 responses may not only be evoking a
sub-optimal response but may also be sacriﬁcing the development of
other CD8+T-cell responses that would bemore capable of restricting
viral replication. Until the molecular factors that deﬁne fully
functional CTL are characterized, individual HIV-speciﬁc CD8+ T-cell
responses cannot be assumed to be placing equal pressure on viral
replication. Only those that show speciﬁc correlation with good
clinical outcome or selection of conﬁrmed escape mutations that
decrease viral ﬁtness should be highlighted as examples of putative
protective correlates.
Materials and methods
Cell lines and peripheral blood mononuclear cells (PBMCs)
For production of viral particles, 293T cells (ATCC) were maintained
in Dulbecco modiﬁed Eagle's media (DMEM) supplemented with 10%
fetal bovine serum (FBS) and 100 U/mL penicillin–streptomycin. Viral
particles were puriﬁed using U87 human astroglioma cells expressing
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Program, Cat# 4036) maintained in DMEM with 15% FBS, penicillin–
streptomycin, 1 μg/mL puromycin and 300 μg/mL Geneticin (G418).
Duringmono-infection viral growth assays, CEM-T4 (NIHAIDS Research
and Reference Reagent Program, Cat# 117) cells were maintained in
RPMI-1640 media with 10% FBS, and penicillin–streptomycin. For dual-
infection competition assays, PBMCs were puriﬁed from an HIV-
uninfected donor using Ficoll-Hypaque density gradient centrifugation
from venous blood draw samples. Cells were maintained in RPMI-1640
with 10% FBS, penicillin–streptomycin and stimulated with 2 μg/mL
phytohemagglutinin (PHA) and 1 ng/mL interleukin-2 (IL-2) for 3 days
before use in dual-infection assays.
vif variant plasmids
To facilitate detection of SL9 mutated viruses in heteroduplex
tracking assays (HTA), synonymous mutations were engineered
within a 40 bp vif cassette of the HIV genome within the context of
pLAI.2 (NIH AIDS Research and Reference Reagent Program, Cat#
2532). These mutations have been utilized in a pNL4-3 plasmid clone
of HIV with no observable ﬁtness impact on resultant viruses (Liu
et al., 2007; Lobritz et al., 2007; Troyer et al., 2005). For the purposes
of this study, the consensus vif sequence in pLAI.2 was termed vifA
and all subsequent mutations of the SL9 epitope regionwere achieved
within a vector backbone containing this sequence. In addition, a
second variant, pLAI.2vifB (5′ - TAG AAT GGA GGA AGA AAA GGT ATA
CCA CGC AGG TGG ACC C - 3′), was created for use as the SL9
consensus reference virus in dual-infection competition assays. This
construct differed from pLAI.2vifA at seven nucleotides (underlined
above) and was generated using overlapping PCR with the resultant
product cloned into the NcoI/ApaI digested pLAI.2 vector. Clones were
screened by colony PCR and sequences conﬁrmed by DNA sequencing.
SL9 variant viral constructs
Mutations in the SL9 epitope region were introduced into the
plasmid backbone pLAI.2 (containing vifA sequence) using overlapping
PCR. Primer pairs incorporating speciﬁc SL9 changes were designed
using PrimerX software (www.bioinformatics.org/primerx/). These
were used in combination with external primers (5′ - GCG GCC GCT CTA
GAACTAGTGGATCTTA - 3′ and5′ - CATATGGCATGCACTGGATGCACT
CT - 3′). The resultant product was sub-cloned into XbaI/SphI digested
pLAI.2. Bacterial transformants were screened by colony PCR and the
desired SL9 epitope sequence alterationswere conﬁrmedby sequencing.
Transfections
Large-scale plasmid puriﬁcations of pLAI.2-SL9 variant constructs
were prepared using QIAGEN Plasmid Midi kit (Qiagen Inc. Canada,
Mississauga, ON). 293T cells were transfected in 100 mm tissue
culture dishes using Lipofectamine 2000 (Invitrogen Canada Inc.,
Burlington, ON) according to the manufacturer's instructions.
Seventy-two hours post-transfection, supernatants (SN) containing
viral particles were removed from the cell monolayer and clariﬁed by
slow speed centrifugation (1000 ×g, 5 min). Expression of viral
proteins was conﬁrmed in the collected supernatant using a capture
enzyme-linked immunosorbent assay (ELISA) for the HIV-1 capsid
protein (p24) (SAIC-Frederick, Inc., Frederick, MD).
Puriﬁcation of infectious viral particles
To ensure high titer infectious viral stocks for subsequent assays,
initial transfection supernatant was passaged through U87.CD4.CXCR4
cells. Brieﬂy, 1 mL of transfection SN was used to infect 6×105 U87.
CD4.CXCR4 cells in a T75 tissue culture ﬂask. After an absorption
period of 3 h at 37 °C, the cells were washed with PBS andsubsequently maintained in 8 mL of media. The production of HIV
p24 was assessed using ELISA every 2 days to monitor viral expansion.
Culture supernatant was collected at peak p24 levels. Sequence
analysis of the region encompassing the SL9 epitope (255 bp upstream
and 315 bp downstream) was performed to ensure no reversion or
additional mutation had accrued during passage. Supernatants
containing high levels of p24 were combined, clariﬁed by slow
speed centrifugation and puriﬁed through 0.45 μm-pore-size ﬁlters
and stored at −85 °C.
TCID50 assays and calculations
Viral stocks were used in limiting dilution 50% tissue culture
infection dose (TCID50) assays as previously described (Ball et al.,
2003). Brieﬂy, stocks were used to infect either 105 CEM-T4 cells or
PBMCs in a 10-fold dilution series in 96-well culture plates. Each
dilution was plated in triplicate. At 7 days post-infection (dpi), p24
levels were assessed to determine the level of productive infection for
each dilution. TCID50 was calculated according to the Reed–Muench
methodology (Reed and Muench, 1938).
Determination of released and intracellular p24
293T cells or U87.CD4.CXCR4 cells were either transfected with
SL9-variant plasmids or exposed to transfection supernatant respec-
tively. All transfections and infections were done in triplicate.
Supernatants and cells were collected 72 h post-transfection or
6 days post-infection, respectively. In the U87.CD4.CXCR4 experi-
ments, the inoculum for each virus was equalized to 20 ng of post-
transfection p24 to allow for expansion from the same number of
initial viral particles. Supernatants were clariﬁed by slow speed
centrifugation and cells were lysed using CelLyse (Sigma) according to
the manufacturer's instructions. HIV p24 ELISA was utilized for
quantiﬁcation of viral protein retained in the cellular fraction or
released into the culture supernatant.
Viral mono-infections
CEM-T4 cells were inoculated in triplicate at a multiplicity of
infection (MOI) of 0.01. Viral stocks were used to infect cells by
spinoculation as previously described (O'Doherty et al., 2000).
Infected culture supernatant was sampled every two days and fresh
media was supplemented. All infections were performed in triplicate
and experiments were replicated at least three times to conﬁrm any
observations. Supernatants were clariﬁed by centrifugation and
assayed for HIV p24 content using ELISA to monitor viral growth
kinetics. Average p24 values for each viral variant were comparedwith
that of the LAI control virus at every time point to determine whether
signiﬁcant differences in growth kinetics were evident.
Viral RNA collection and sequencing
To conﬁrm stability of the introducedmutations in the viral genome,
viral RNA was sequenced over a region spanning the SL9 region and
extending 255 bp upstream and 315 bp downstream to assess any
potential compensating mutations in proximity to the SL9 epitope.
Supernatants were sampled continuously during viral stock production
and subsequent growthmonitoring experiments. Viral RNAwaspuriﬁed
using the QiaAmp Viral RNA kit (Qiagen) and then subjected to dye-
terminationnucleotide sequencingusingprimers 5′ -TGGGTGCGAGAG
CGT CRR TAT TAAG - 3′/5′ - GCTGAAAACATGGGTATTACY TCTGG - 3′.
Dual-infection competition assays
PBMCs were collected from an HIV-uninfected individual whose
cells had previously been described to support a median growth rate
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al., 2005). Competition assays were conducted as previously described
(Abraha et al., 2005). Brieﬂy, 3 days post-stimulationwith PHA and IL-
2, 5×105 cells were simultaneously inoculated at an MOI of 0.0001
with both LAIvifB (SL9 consensus) and an individual SL9-variant
(coding vifA) in 48-well tissue culture plates. Mono-infections for
each virus were run in parallel to the competition cultures.
Competition cultures conducted between LAIvifA and LAIvifB were
also included to conﬁrm that the synonymous changes in Vif had no
effect on viral ﬁtness (Fig. 5, Supplementary Fig. 1). All dual-infection
assays were conducted in triplicate for each combination of viruses. At
7 dpi, cell pellets and clariﬁed supernatants were harvested and stored
at −80 °C for future analysis. Samples from cell-free supernatants
were subjected to limiting dilution reverse transcriptase (RT) assays
as previously described (Lobritz et al., 2007) to conﬁrm outgrowth of
HIV in all infected cultures and lack thereof in negative controls.
Heteroduplex tracking assays (HTA)
DNA was extracted from competition culture cell pellets using the
QiaAmp DNA Blood Mini kit (Qiagen) and the vif region of the HIV
genome was ampliﬁed using external primers (5′ - GCA AAG CTC CTC
TGG AAA GGT GAA GGG - 3′/5′ - CTT CCA CTC CTG CCC AAG TAT CCC -
3′) and internal primers (5′ - GAA AGAGAC TGG CAT CTG GGT CAG GG
- 3′/5′ - GTC TTC TGG GGC TTG TTC CAT CTA TCC - 3′). The nested PCR
products were denatured and allowed to reanneal in the presence of
radioactive probes speciﬁc for vifA. Each reaction mix contained DNA
annealing buffer (100mMNaCl,10mMTris–HCl [pH7.8], 2mMEDTA),
10 μL of unlabelled nested PCR product, and 400 cpm of radioactive
probe. The resultant DNA homo and heteroduplexes were separated
on Tris–Borate EDTA buffer-containing 10% non-denaturing polyacry-
lamide gels for 4 h at 200V. Gels were dried and exposed to
phosphorscreens overnight at room temperature in the dark.
Densitometry measurements of homo and heteroduplex bands were
acquired from phosphorscreen images using a Bio-Rad phosphor-
imager and QuantityOne software.
Calculation of relative ﬁtness values
Replicative ﬁtness capacity of each of the SL9 viral variants was
determined as previously described (Abraha et al., 2005). Brieﬂy, the
relative abundance of heteroduplexes in competition culture was
compared to that in the relevant mono-infection. The amount of virus
in competition culture (f0) was divided by the initial proportion of
that virus in the inoculum (i0). This represents the relative ﬁtness
value (w= f0/i0) for a given virus. A value of w=1.0 represents equal
ﬁtness of the two viruses in competition, i.e. that each proviral
sequence comprised 50% of the total viral population at the conclusion
of the culture. Relative ﬁtness values were calculated for each dual-
infection replicate based on the densitometry readings and average
ﬁtness values and standard deviations for virus pairs were derived
using this data.
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